CVS · Q2 2026 Earnings

Bullish

CVS Health

Reported August 5, 2026

30-second summary

Q2 revenue grew 7.3% to $106.1B, beating consensus by 6.0%, and adjusted EPS of $2.58 came in 39.5% above the $1.85 consensus. Management raised FY2026 adjusted EPS by $0.60 to $7.90–$8.10, GAAP EPS by $0.60 to $6.84–$7.04, revenue floor by $9.0B to "at least $414.0B," and operating cash flow floor by $2.0B to "at least $11.5B" — the OpCF raise fully closes the $0.5B gap the Q1 brief flagged and puts the floor $1.5B above the original December Investor Day framing. The magnitude of the raise (+8.1% on adjusted EPS midpoint, +21% on OpCF floor) is materially larger than the Q1 raise (+4.2% EPS, +5.6% OpCF), yet management maintained the "cautious view for remainder of year" language verbatim from Q1 — the disclosure gap between what the numbers say and what the tone says has widened.

Headline numbers

EPS

Q2 FY2026

$2.58

Revenue

Q2 FY2026

$106.10B

+7.3% YoY

+6.0% vs est.

Operating margin

Q2 FY2026

4.4%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$106.10B	$98.92B	+7.3%	$100.43B	+5.6%
EPS	$2.58	$1.81	+42.5%	$2.57	+0.4%
Operating margin	4.4%	2.4%	+199bps	4.7%	-26bps

Guidance

Company raised full-year FY2026 guidance across all metrics (EPS, Adjusted EPS, Revenue, Operating Cash Flow) on stronger H1 performance and Health Care Benefits/Pharmacy segment momentum, while Q2 results beat on both revenue and earnings.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q2 FY2026	—	$106.096 billion	+6.0% above consensus estimate of $100.09B	Beat
GAAP Diluted EPS	Q2 FY2026	—	$2.31	+$0.46 above consensus estimate of $1.85 (39.5% surprise)	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
GAAP Diluted EPS	FY 2026	$6.24 to $6.44	$6.84 to $7.04	+$0.60 to $0.60 at midpoint; low end +$0.60, high end +$0.60	Raised
Adjusted EPS	FY 2026	$7.30 to $7.50	$7.90 to $8.10	+$0.60 to $0.60 at range; low end +$0.60, high end +$0.60	Raised
Total Revenues	FY 2026	At least $405.0 billion	At least $414.0 billion	+$9.0 billion	Raised
Cash Flow from Operations	FY 2026	At least $9.5 billion	At least $11.5 billion	+$2.0 billion	Raised

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Health Care Benefits	$37.538B	$36.258B	+3.5%
Health Services	$51.795B	$46.453B	+11.5%
Pharmacy & Consumer Wellness	$33.816B	$33.581B	+0.7%

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Medical Benefit Ratio (MBR)	87.4%	89.9%	—
Medical Membership	26.0 million	26.7 million	—
Pharmacy Claims Processed (30-day equivalent)	473.0 million	469.0 million	—
Prescriptions Filled (30-day equivalent)	457.0 million	438.1 million	—
Days Claims Payable	41.7 days	40.9 days	—
Health Care Benefits Adjusted Operating Income	$2,426 million	—	—
Health Services Adjusted Operating Income	$1,733 million	—	—
Pharmacy & Consumer Wellness Adjusted Operating Income	$1,475 million	—	—

Management tone

Narrative arc: Q3 2025 stabilization and rationalization → Q4 2025 execution confidence → Q1 2026 cautious raise → Q2 2026 cautious raise (larger).

Two quarters ago at Q4, management moved from Q3's "businesses and markets where we can succeed" footprint-trimming language to the "ambition to be the most trusted health care company in America" framing. At Q1 the tone snapped back to "maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds." At Q2, that exact caution language is repeated verbatim — even as the raise magnitude doubles from Q1 (+$0.30) to Q2 (+$0.60) on adjusted EPS. Management is explicitly choosing not to escalate the tone alongside the numbers. This is the same disclosure discipline visible at Q1 when they refused to flow the 84.6% MBR outperformance into guide — a pattern of conservative guide-setting that has now translated into two consecutive quarters of clean beats.

The operating cash flow arc is where the credibility story matters most. Three quarters ago at Q4, management cut FY2026 OpCF from "at least $10.0B" to "at least $9.0B" and the Q4 brief flagged this as the discordant note against otherwise-improving fundamentals. Two quarters later, the OpCF floor sits at $11.5B — $1.5B above the original December framing. The company has now traded a $1.0B cut for a $2.5B over-recovery in two quarters. The willingness to hold a floor format ("at least $11.5B") rather than convert to a range signals management sees further upside potential, consistent with the Q1 brief's watch item on floor-vs-range framing.

The EPS raise pattern is asymmetric. Q1's $0.30 raise was attributed to "increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments." Q2's $0.60 raise is attributed to the same two segments. Health Services has been excluded from both raises despite double-digit revenue growth in each — the segment is delivering top-line without contributing to the EPS story. That is consistent with the Q3 2025 $240M Caremark drug-mix cut and the "multi-year recontracting" framing management gave for PBM margin recovery. The gap between Health Services revenue momentum and its absence from the EPS raise commentary is the single most important tonal datapoint to track into Q3.

The absence of transcript commentary this quarter is itself notable. The Q1 brief drew heavily on Q&A to establish that MBR outperformance was primarily PYD-driven and that Health Services benefited from timing pull-forward. Without transcript disclosure this quarter, investors are anchoring on a press release that shows a much larger raise than Q1 without the qualitative context that would explain the drivers.

Answers to last quarter's watch list

HCB MBR Q2 print within the 90.5% ± 50bps FY band — MBR came in at 87.4%, still well below the FY guide band on continuing Part D seasonality, though up 280bps sequentially from Q1's 84.6%. The sequential rise is consistent with the ~850bps Q1-to-Q4 seasonal swing management flagged at Q4. Without transcript commentary, whether the outperformance is again PYD-driven or reflects durable core trend improvement cannot be disaggregated — but the $0.60 EPS raise implies management has now been willing to flow some of the "core outperformance" they refused to bake in at Q1.

Resolved positively

Operating cash flow toward closing the remaining $0.5B gap to the original $10.0B framing — the floor was raised to "at least $11.5B" from "at least $9.5B," a $2.0B raise that not only closes the gap but pushes $1.5B above the original December framing. Floor format was maintained rather than converted to a range, which typically signals further upside potential.

Resolved positively

Tennessee PBM litigation status and other state-level copycats — the press release did not update the Tennessee litigation status disclosed at Q1 ("considering legal action" with mid-2028 implementation). No new state-level PBM-separation legislation was called out. Absent transcript commentary, no update on the mid-teens EPS CAGR through 2028 framing.

Continue monitoring

PCW revenue growth re-acceleration as Rite Aid integration laps — Q2 PCW at +0.7% YoY (vs Q1 +0.2%) shows minimal re-acceleration despite the integration now fully in the base. However, PCW was cited as a contributor to the FY EPS raise, meaning margin expansion is offsetting the flat top line. The segment adjusted operating income of $1.48B is the key profit driver.

Continue monitoring

Caremark 2027 selling-season early indicators and TrueCost adoption — the Q2 release did not refresh the $6B 2026 wins figure or provide 2027 selling-season commentary. Historically CVS discloses selling-season wins at Q3.

Continue monitoring

AI investment quantification and Health 100 platform launch detail — no specific investment dollar sizing or Health 100 platform KPIs disclosed in the Q2 release. The "consumer-based healthcare technology company" framing from Q1 was not repeated in the press release language.

Continue monitoring

What to watch into next quarter

Whether Q3 delivers a third consecutive FY EPS raise or holds at $7.90–$8.10 — the Q1→Q2 raise magnitude doubled from $0.30 to $0.60; a Q3 hold would confirm management has now caught up to the run-rate, while a further raise would extend the disclosure-conservatism pattern. Watch particularly whether Health Services enters the raise-driver commentary for the first time since December.

Q3 MBR print and full-year MBR exit rate — Q1 84.6%, Q2 87.4%; the FY guide of 90.5% ± 50bps implies a ~94% Q4 exit. Watch whether Q3 comes in above 90% (consistent with the guide) or continues to print below-band, which would suggest either further raise potential or that the FY MBR guide has become mechanically conservative.

Caremark 2027 selling-season wins figure — Q3 is historically when CVS discloses next-year Caremark wins ($6B disclosed at Q3 2025 for 2026). Watch whether the 2027 figure exceeds, matches, or falls short of the $6B baseline, and whether TrueCost adoption is named as an adoption driver.

Health Services entering the FY EPS raise-driver language — HSS has been excluded from both Q1 and Q2 raise commentary despite double-digit revenue growth. A Q3 mention would signal the Caremark drug-mix headwind is receding; continued absence would suggest the multi-year recontracting drag persists.

Operating cash flow floor conversion to a range or further raise — the $11.5B floor now sits $1.5B above the original December framing; watch whether Q3 converts to a range, which would signal management sees the bulk of the upside recognized, versus another floor raise, which would signal continued working-capital tailwinds.

Tennessee PBM litigation filing and MA 2027 final rate notice — both were flagged as unresolved at Q1; watch for legal-action filing and any quantification of the "leading stars position entering 2027" against the "disappointing" preliminary rate notice.

Sources

CVS Health Q2 FY2026 press release (SEC 8-K, Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/64803/000006480326000097/cvs_ex99x1q2-26.htm
CVS Health Q1 FY2026 brief (Tapebrief, prior-quarter reference).
CVS Health Q4 FY2025 brief (Tapebrief, prior-quarter reference for December Investor Day baseline and cash flow arc).
CVS Health Q3 FY2025 brief (Tapebrief, prior-quarter reference for Caremark drug-mix context).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.